Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 12;73(49):1124-1128.
doi: 10.15585/mmwr.mm7349a3.

New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, October 2024

Sarah Schillie, Jamie Loehr, Wilbur H Chen, Charlotte A Moser, Gabrielle Cooper, Cheryl Isenhour, Lucy A McNamara

New Dosing Interval and Schedule for the Bexsero MenB-4C Vaccine: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, October 2024

Sarah Schillie et al. MMWR Morb Mortal Wkly Rep. .

Abstract

Two meningococcal serogroup B vaccines are licensed for use in the United States. In August 2024, the Food and Drug Administration (FDA) changed the label for the meningococcal serogroup B MenB-4C vaccine (Bexsero) from a 2-dose schedule (intervals of 0 and ≥1 month) to a 2-dose schedule (0 and 6 months) and added a 3-dose schedule (0, 1-2, and 6 months), based on new immunogenicity data. On October 24, 2024, the Advisory Committee on Immunization Practices (ACIP) voted to update its recommendations for the MenB-4C dosing interval and schedule to align with the new FDA label. ACIP recommends extending the interval for the 2-dose series of MenB-4C from 0 and ≥1 month to 0 and 6 months for healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making and has added a recommendation for a 3-dose series with doses administered at 0, 1-2, and 6 months for persons aged ≥10 years at increased risk. The updated ACIP recommendations for MenB-4C align with existing ACIP recommendations for the other FDA-licensed meningococcal serogroup B vaccine, MenB-FHbp (Trumenba).

PubMed Disclaimer

Conflict of interest statement

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Charlotte A. Moser reports receipt of an advance from Columbia University Press for co-authoring “Vaccines and Your Family: Separating Fact from Fiction” in 2024. No other potential conflicts of interest were disclosed.

References

    1. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020;69(No. RR-9):1–41. 10.15585/mmwr.rr6909a1 - DOI - PMC - PubMed
    1. Collins JP, Crowe SJ, Ortega-Sanchez IR, et al. Use of the Pfizer pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices—United States, 2023. MMWR Morb Mortal Wkly Rep 2024;73:345–50. 10.15585/mmwr.mm7315a4 - DOI - PMC - PubMed
    1. Food and Drug Administration. Package insert: Bexsero. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https://www.fda.gov/media/90996/download
    1. Schillie S. Summary of work group considerations regarding Bexsero interval and dosing change [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 24, 2024. https://www.cdc.gov/acip/meetings/presentation-slides-october-23-24-2024...
    1. CDC. ACIP Evidence to Recommendation user’s guide. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://www.cdc.gov/acip/media/pdfs/2024/09/ACIP-EtR-Users-Guide_October...

LinkOut - more resources